17.9.2020 |
EN |
Official Journal of the European Union |
C 308/9 |
Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the second half of 2019
(2020/C 308/06)
Subcommittee I on the free movement of goods
To be noted by the EEA Joint Committee
With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July – 31 December 2019, at their meeting on 20 March 2020.
Annex I |
List of new marketing authorisations |
Annex II |
List of renewed marketing authorisations |
Annex III |
List of extended marketing authorisations |
Annex IV |
List of withdrawn marketing authorisations |
Annex V |
List of suspended marketing authorisations |
ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July–31 December 2019:
EU-Number |
Product |
Country |
Date of authorisation |
EU/2/19/240 |
Afoxolaner Merial |
Iceland |
30.8.2019 |
EU/1/19/1398 |
Arsenic Trioxide Accord |
Iceland |
2.12.2019 |
EU/1/19/1398 |
Arsenic Trioxide Accord |
Liechtenstein |
31.12.2019 |
EU/1/19/1398 |
Arsenic Trioxide Accord |
Norway |
26.11.2019 |
EU/2/18/228 |
Arti-Cell Forte |
Iceland |
16.7.2019 |
EU/1/19/1382 |
Azacitidin Celgene |
Iceland |
29.8.2019 |
EU/1/19/1382 |
Azacitidin Celgene |
Liechtenstein |
31.8.2019 |
EU/1/19/1382 |
Azacitidin Celgene |
Norway |
8.8.2019 |
EU/1/19/1406 |
BAQSIMI |
Iceland |
30.12.2019 |
EU/1/19/1406 |
BAQSIMI |
Liechtenstein |
31.12.2019 |
EU/1/19/1397 |
Bortezomib Fresenius Kabi |
Iceland |
29.11.2019 |
EU/1/19/1397 |
Bortezomib Fresenius Kabi |
Liechtenstein |
31.12.2019 |
EU/1/19/1397 |
Bortezomib Fresenius Kabi |
Norway |
10.12.2019 |
EU/1/19/1365 |
Cufence |
Iceland |
9.10.2019 |
EU/1/19/1365 |
Cufence |
Liechtenstein |
31.8.2019 |
EU/1/19/1365 |
Cufence |
Norway |
12.8.2019 |
EU/1/19/1386 |
Deferasirox Mylan |
Iceland |
11.10.2019 |
EU/1/19/1386 |
Deferasirox Mylan |
Liechtenstein |
31.10.2019 |
EU/1/19/1386 |
Deferasirox Mylan |
Norway |
8.10.2019 |
EU/1/19/1370 |
Dovato |
Iceland |
19.7.2019 |
EU/1/19/1370 |
Dovato |
Liechtenstein |
31.8.2019 |
EU/1/19/1370 |
Dovato |
Norway |
04.07.2019 |
EU/1/19/1389 |
Epidyolex |
Iceland |
18.10.2019 |
EU/1/19/1389 |
Epidyolex |
Liechtenstein |
31.10.2019 |
EU/1/19/1389 |
Epidyolex |
Norway |
16.10.2019 |
EU/1/19/1392 |
Ervebo |
Iceland |
4.12.2019 |
EU/1/19/1392 |
Ervebo |
Liechtenstein |
31.12.2019 |
EU/1/19/1392 |
Ervebo |
Norway |
19.11.2019 |
EU/1/19/1374 |
Esperoct |
Liechtenstein |
31.8.2019 |
EU/1/19/1411 |
Evenity |
Iceland |
12.12.2019 |
EU/1/19/1411 |
Evenity |
Liechtenstein |
31.12.2019 |
EU/2/19/242 |
EVICTO |
Iceland |
27.8.2019 |
EU/2/19/242 |
EVICTO |
Liechtenstein |
31.8.2019 |
EU/2/19/242 |
EVICTO |
Norway |
13.08.2019 |
EU/1/19/1384 |
Giapreza |
Iceland |
29.8.2019 |
EU/1/19/1384 |
Giapreza |
Liechtenstein |
31.8.2019 |
EU/1/19/1384 |
Giapreza |
Norway |
25.09.2019 |
EU/1/19/1375 |
Grasustek |
Iceland |
24.7.2019 |
EU/1/19/1375 |
Grasustek |
Norway |
31.10.2019 |
EU/2/19/245 |
Gumbohatch |
Iceland |
29.11.2019 |
EU/2/19/245 |
Gumbohatch |
Liechtenstein |
31.12.2019 |
EU/2/18/226 |
HorStem |
Iceland |
16.7.2019 |
EU/1/17/1216 |
Imraldi |
Norway |
16.09.2019 |
EU/1/19/1390 |
Inbrija |
Iceland |
11.10.2019 |
EU/1/19/1390 |
Inbrija |
Liechtenstein |
31.10.2019 |
EU/1/19/1390 |
Inbrija |
Norway |
16.10.2019 |
EU/1/19/1396 |
Ivozall |
Iceland |
28.11.2019 |
EU/1/19/1396 |
Ivozall |
Norway |
26.11.2019 |
EU/1/19/1383 |
Lacosamid UCB |
Iceland |
3.9.2019 |
EU/1/19/1383 |
Lacosamid UCB |
Liechtenstein |
31.8.2019 |
EU/1/19/1383 |
Lacosamid UCB |
Norway |
18.10.2019 |
EU/1/19/1376 |
LIBTAYO |
Iceland |
19.7.2019 |
EU/1/19/1376 |
LIBTAYO |
Liechtenstein |
31.8.2019 |
EU/1/19/1376 |
LIBTAYO |
Norway |
05.8.2019 |
EU/1/19/1381 |
LysaKare |
Iceland |
26.8.2019 |
EU/1/19/1381 |
LysaKare |
Liechtenstein |
31.8.2019 |
EU/1/19/1381 |
LysaKare |
Norway |
12.8.2019 |
EU/1/18/1301 |
Mepsevii |
Liechtenstein |
31.8.2019 |
EU/2/19/247 |
Mirataz |
Iceland |
30.12.2019 |
EU/2/19/247 |
Mirataz |
Liechtenstein |
31.12.2019 |
EU/2/19/241 |
NASYM |
Iceland |
27.8.2019 |
EU/2/19/241 |
NASYM |
Liechtenstein |
31.8.2019 |
EU/2/19/241 |
NASYM |
Norway |
16.8.2019 |
EU/2/19/246 |
Neptra |
Iceland |
30.12.2019 |
EU/2/19/246 |
Neptra |
Liechtenstein |
31.12.2019 |
EU/2/19/244 |
Nobivac Myxo-RHD Plus |
Iceland |
4.12.2019 |
EU/2/19/244 |
Nobivac Myxo-RHD Plus |
Liechtenstein |
31.12.2019 |
EU/1/19/1364 |
Nuceiva |
Iceland |
18.10.2019 |
EU/1/19/1364 |
Nuceiva |
Norway |
18.10.2019 |
EU/1/18/1320 |
Onpattro |
Liechtenstein |
31.12.2019 |
EU/1/19/1388 |
Polivy |
Liechtenstein |
31.12.2019 |
EU/1/19/1379 |
Posaconazole Accord |
Iceland |
28.8.2019 |
EU/1/19/1379 |
Posaconazole Accord |
Liechtenstein |
31.8.2019 |
EU/1/19/1379 |
Posaconazole Accord |
Norway |
26.8.2019 |
EU/1/19/1380 |
Posaconazole AHCL |
Iceland |
27.8.2019 |
EU/1/19/1380 |
Posaconazole AHCL |
Liechtenstein |
31.8.2019 |
EU/1/19/1380 |
Posaconazole AHCL |
Norway |
12.8.2019 |
EU/1/19/1401 |
Qtrilmet |
Iceland |
18.11.2019 |
EU/1/19/1401 |
Qtrilmet |
Liechtenstein |
31.12.2019 |
EU/1/19/1401 |
Qtrilmet |
Norway |
6.12.2019 |
EU/1/19/1393 |
Quofenix |
Iceland |
30.12.2019 |
EU/1/19/1393 |
Quofenix |
Liechtenstein |
31.12.2019 |
EU/1/19/1400 |
Rhokiinsa |
Iceland |
5.12.2019 |
EU/1/19/1400 |
Rhokiinsa |
Norway |
17.12.2019 |
EU/1/19/1404 |
Rinvoq |
Iceland |
30.12.2019 |
EU/1/19/1404 |
Rinvoq |
Liechtenstein |
31.12.2019 |
EU/1/19/1387 |
Senstend |
Iceland |
4.12.2019 |
EU/1/19/1387 |
Senstend |
Norway |
4.12.2019 |
EU/2/19/243 |
Simparica Trio |
Iceland |
10.10.2019 |
EU/2/19/243 |
Simparica Trio |
Liechtenstein |
31.10.2019 |
EU/2/19/243 |
Simparica Trio |
Norway |
11.11.2019 |
EU/1/19/1369 |
Sixmo |
Iceland |
17.7.2019 |
EU/1/19/1369 |
Sixmo |
Norway |
15.7.2019 |
EU/1/19/1410 |
Spravato |
Liechtenstein |
31.12.2019 |
EU/1/19/1372 |
Striascan |
Iceland |
2.7.2019 |
EU/1/19/1372 |
Striascan |
Liechtenstein |
31.8.2019 |
EU/1/19/1372 |
Striascan |
Norway |
11.7.2019 |
EU/1/19/1377 |
Talzenna |
Iceland |
16.7.2019 |
EU/1/19/1377 |
Talzenna |
Norway |
15.7.2019 |
EU/1/19/1359 |
Trogarzo |
Iceland |
5.11.2019 |
EU/1/19/1359 |
Trogarzo |
Liechtenstein |
31.10.2019 |
EU/1/19/1359 |
Trogarzo |
Norway |
18.10.2019 |
EU/1/19/1371 |
Ultomiris |
Iceland |
22.7.2019 |
EU/1/19/1371 |
Ultomiris |
Liechtenstein |
31.8.2019 |
EU/1/19/1371 |
Ultomiris |
Norway |
17.7.2019 |
EU/1/19/1385 |
VITRAKVI |
Iceland |
5.11.2019 |
EU/1/19/1385 |
VITRAKVI |
Liechtenstein |
31.10.2019 |
EU/1/19/1385 |
VITRAKVI |
Norway |
18.10.2019 |
EU/1/18/1312 |
Xerava |
Liechtenstein |
31.12.2019 |
EU/1/19/1399 |
Xospata |
Iceland |
6.11.2019 |
EU/1/19/1399 |
Xospata |
Norway |
30.10.2019 |
EU/1/19/1366 |
Xromi |
Iceland |
19.7.2019 |
EU/1/19/1366 |
Xromi |
Liechtenstein |
31.8.2019 |
EU/1/19/1366 |
Xromi |
Norway |
17.7.2019 |
ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July–31 December 2019:
EU-Number |
Product |
Country |
Date of authorisation |
EU/1/14/944 |
Abasaglar |
Iceland |
28.8.2019 |
EU/1/14/944 |
Abasaglar |
Liechtenstein |
31.8.2019 |
EU/1/14/944 |
Abasaglar |
Norway |
16.8.2019 |
EU/1/12/794 |
ADCETRIS |
Iceland |
18.10.2019 |
EU/1/12/794 |
ADCETRIS |
Norway |
29.10.2019 |
EU/1/09/578 |
Adjupanrix |
Iceland |
29.8.2019 |
EU/1/09/578 |
Adjupanrix |
Norway |
12.8.2019 |
EU/1/17/1214 |
Bavencio |
Liechtenstein |
31.10.2019 |
EU/2/14/176 |
Bovela |
Iceland |
15.11.2019 |
EU/2/14/176 |
Bovela |
Liechtenstein |
31.12.2019 |
EU/2/14/176 |
Bovela |
Norway |
27.11.2019 |
EU/1/14/963 |
Brimica Genuair |
Iceland |
29.8.2019 |
EU/1/14/963 |
Brimica Genuair |
Liechtenstein |
31.8.2019 |
EU/1/14/963 |
Brimica Genuair |
Norway |
20.09.2019 |
EU/1/14/951 |
Busulfan Fresenius Kabi |
Norway |
15.07.2019 |
EU/1/14/974 |
Cerdelga |
Iceland |
30.12.2019 |
EU/1/14/974 |
Cerdelga |
Liechtenstein |
31.12.2019 |
EU/1/14/975 |
Clopidogrel ratiopharm |
Iceland |
15.11.2019 |
EU/1/14/975 |
Clopidogrel ratiopharm |
Liechtenstein |
31.12.2019 |
EU/1/14/975 |
Clopidogrel ratiopharm |
Norway |
9.12.2019 |
EU/1/13/890 |
Cometriq |
Norway |
3.07.2019 |
EU/1/14/980 |
Cosentyx |
Iceland |
10.9.2019 |
EU/1/14/980 |
Cosentyx |
Liechtenstein |
31.10.2019 |
EU/1/14/980 |
Cosentyx |
Norway |
18.09.2019 |
EU/1/17/1262 |
Crysvita |
Iceland |
27.12.2019 |
EU/1/17/1262 |
Crysvita |
Liechtenstein |
31.12.2019 |
EU/1/14/957 |
Cyramza |
Iceland |
10.10.2019 |
EU/1/14/957 |
Cyramza |
Norway |
3.10.2019 |
EU/1/14/964 |
Duaklir Genuair |
Iceland |
29.8.2019 |
EU/1/14/964 |
Duaklir Genuair |
Liechtenstein |
31.8.2019 |
EU/1/14/964 |
Duaklir Genuair |
Norway |
20.09.2019 |
EU/1/14/960 |
DUAVIVE |
Iceland |
15.11.2019 |
EU/1/14/960 |
DUAVIVE |
Liechtenstein |
31.12.2019 |
EU/1/14/960 |
DUAVIVE |
Norway |
9.12.2019 |
EU/1/14/972 |
Duloxetin Lilly |
Iceland |
28.8.2019 |
EU/1/14/972 |
Duloxetin Lilly |
Liechtenstein |
31.8.2019 |
EU/1/14/972 |
Duloxetin Lilly |
Norway |
30.8.2019 |
EU/1/14/983 |
Exviera |
Iceland |
10.10.2019 |
EU/1/14/983 |
Exviera |
Norway |
18.10.2019 |
EU/1/09/601 |
Firdapse |
Iceland |
30.8.2019 |
EU/1/09/601 |
Firdapse |
Liechtenstein |
31.8.2019 |
EU/1/09/601 |
Firdapse |
Norway |
18.9.2019 |
EU/1/14/958 |
Harvoni |
Iceland |
29.8.2019 |
EU/1/14/958 |
Harvoni |
Liechtenstein |
31.8.2019 |
EU/1/14/958 |
Harvoni |
Norway |
16.8.2019 |
EU/1/14/945 |
IMBRUVICA |
Iceland |
16.7.2019 |
EU/1/14/945 |
IMBRUVICA |
Liechtenstein |
31.8.2019 |
EU/1/14/945 |
IMBRUVICA |
Norway |
2.7.2019 |
EU/1/09/531 |
Instanyl |
Iceland |
23.7.2019 |
EU/1/09/531 |
Instanyl |
Liechtenstein |
31.8.2019 |
EU/1/09/531 |
Instanyl |
Norway |
16.7.2019 |
EU/1/15/994 |
Kengrexal |
Iceland |
27.12.2019 |
EU/1/15/994 |
Kengrexal |
Liechtenstein |
31.12.2019 |
EU/1/14/965 |
Ketoconazole HRA |
Iceland |
5.9.2019 |
EU/1/14/965 |
Ketoconazole HRA |
Liechtenstein |
31.8.2019 |
EU/1/14/965 |
Ketoconazole HRA |
Norway |
12.8.2019 |
EU/1/14/955 |
Lymphoseek |
Iceland |
18.10.2019 |
EU/1/14/955 |
Lymphoseek |
Norway |
25.9.2019 |
EU/1/14/959 |
Lynparza |
Iceland |
10.10.2019 |
EU/1/14/959 |
Lynparza |
Norway |
18.10.2019 |
EU/1/14/962 |
Moventig |
Iceland |
9.10.2019 |
EU/1/14/962 |
Moventig |
Norway |
31.10.2019 |
EU/1/09/591 |
Multaq |
Iceland |
9.10.2019 |
EU/1/09/591 |
Multaq |
Norway |
21.10.2019 |
EU/2/14/177 |
Nexgard Spectra |
Iceland |
15.11.2019 |
EU/2/14/177 |
Nexgard Spectra |
Liechtenstein |
31.12.2019 |
EU/2/14/177 |
Nexgard Spectra |
Norway |
27.11.2019 |
EU/1/16/1094 |
Ninlaro |
Iceland |
18.10.2019 |
EU/1/14/979 |
Ofev |
Iceland |
18.10.2019 |
EU/1/14/979 |
Ofev |
Norway |
21.10.2019 |
EU/2/14/170 |
Osurnia |
Iceland |
22.7.2019 |
EU/2/14/170 |
Osurnia |
Liechtenstein |
31.8.2019 |
EU/2/14/170 |
Osurnia |
Norway |
16.7.2019 |
EU/1/14/981 |
Otezla |
Iceland |
30.8.2019 |
EU/1/14/981 |
Otezla |
Liechtenstein |
31.8.2019 |
EU/1/14/981 |
Otezla |
Norway |
28.9.2019 |
EU/1/16/1089 |
Pandemic influenza vaccine H5N1 AstraZeneca |
Norway |
8.7.2019 |
EU/2/14/175 |
Porcilis PCV M Hyo |
Iceland |
9.10.2019 |
EU/2/14/175 |
Porcilis PCV M Hyo |
Norway |
14.10.2019 |
EU/1/14/977 |
Rasagiline ratiopharm |
Iceland |
21.10.2019 |
EU/1/14/967 |
Rezolsta |
Iceland |
28.8.2019 |
EU/1/14/967 |
Rezolsta |
Liechtenstein |
31.8.2019 |
EU/1/14/967 |
Rezolsta |
Norway |
16.8.2019 |
EU/1/14/970 |
RIXUBIS |
Iceland |
5.12.2019 |
EU/1/15/992 |
Saxenda |
Iceland |
27.12.2019 |
EU/1/15/992 |
Saxenda |
Liechtenstein |
31.12.2019 |
EU/1/14/969 |
SCENESSE |
Iceland |
5.12.2019 |
EU/1/14/969 |
SCENESSE |
Liechtenstein |
31.12.2019 |
EU/1/14/969 |
SCENESSE |
Norway |
6.12.2019 |
EU/1/14/978 |
Senshio |
Iceland |
6.11.2019 |
EU/1/14/978 |
Senshio |
Liechtenstein |
31.10.2019 |
EU/1/14/978 |
Senshio |
Norway |
21.11.2019 |
EU/1/14/952 |
Sevelamer carbonate Winthrop |
Iceland |
15.11.2019 |
EU/1/14/952 |
Sevelamer carbonate Winthrop |
Liechtenstein |
31.12.2019 |
EU/1/14/952 |
Sevelamer carbonate Winthrop |
Norway |
27.11.2019 |
EU/2/14/179 |
Suvaxyn CSF Marker |
Iceland |
15.11.2019 |
EU/2/14/179 |
Suvaxyn CSF Marker |
Liechtenstein |
31.12.2019 |
EU/2/14/179 |
Suvaxyn CSF Marker |
Norway |
27.11.2019 |
EU/1/14/961 |
Tadalafil Mylan |
Iceland |
28.8.2019 |
EU/1/14/961 |
Tadalafil Mylan |
Liechtenstein |
31.8.2019 |
EU/1/14/961 |
Tadalafil Mylan |
Norway |
12.8.2019 |
EU/1/13/902 |
Translarna |
Iceland |
28.8.2019 |
EU/1/13/902 |
Translarna |
Liechtenstein |
31.8.2019 |
EU/1/13/902 |
Translarna |
Norway |
26.8.2019 |
EU/1/14/971 |
TREVICTA |
Iceland |
6.12.2019 |
EU/1/14/971 |
TREVICTA |
Norway |
4.12.2019 |
EU/1/14/940 |
Triumeq |
Iceland |
21.10.2019 |
EU/1/14/940 |
Triumeq |
Norway |
16.8.2019 |
EU/1/14/956 |
Trulicity |
Iceland |
29.8.2019 |
EU/1/14/956 |
Trulicity |
Liechtenstein |
31.8.2019 |
EU/1/14/956 |
Trulicity |
Norway |
25.9.2019 |
EU/1/07/440 |
Tyverb |
Iceland |
9.10.2019 |
EU/1/07/440 |
Tyverb |
Norway |
21.10.2019 |
EU/1/14/954 |
Vargatef |
Iceland |
29.8.2019 |
EU/1/14/954 |
Vargatef |
Liechtenstein |
31.8.2019 |
EU/1/14/954 |
Vargatef |
Norway |
2.9.2019 |
EU/1/07/423 |
Vectibix |
Iceland |
9.10.2019 |
EU/1/07/423 |
Vectibix |
Norway |
21.10.2019 |
EU/1/14/982 |
Viekirax |
Iceland |
18.10.2019 |
EU/1/14/982 |
Viekirax |
Norway |
18.10.2019 |
EU/1/14/941 |
Vizamyl |
Iceland |
28.8.2019 |
EU/1/14/941 |
Vizamyl |
Liechtenstein |
31.8.2019 |
EU/1/14/941 |
Vizamyl |
Norway |
12.8.2019 |
EU/1/14/984 |
Xadago |
Iceland |
9.10.2019 |
EU/1/14/947 |
Xultophy |
Iceland |
21.10.2019 |
EU/1/14/947 |
Xultophy |
Norway |
7.8.2019 |
EU/1/14/986 |
Xydalba |
Iceland |
12.12.2019 |
EU/1/14/986 |
Xydalba |
Liechtenstein |
31.12.2019 |
ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July–31 December 2019:
EU-Number |
Product |
Country |
Date of authorisation |
EU/1/13/853/006-014 |
Remsima |
Iceland |
5.12.2019 |
EU/1/15/1043/003-006 |
Nucala |
Iceland |
28.8.2019 |
EU/1/15/1043/003-006 |
Nucala |
Norway |
31.7.2019 |
|
|
|
|
EU/1/17/1216/009 |
Imraldi |
Iceland |
30.8.2019 |
EU/1/17/1220/002 |
Tecentriq |
Iceland |
30.8.2019 |
EU/1/17/1220/002 |
Tecentriq |
Norway |
26.8.2019 |
|
|
|
|
EU/1/12/782/006 |
Kalydeco |
Norway |
17.12.2019 |
ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July–31 December 2019:
EU-Number |
Product |
Country |
Date of withdrawal |
EU/1/16/1122 |
Aerivio Spiromax |
Iceland |
21.10.2019 |
EU/1/16/1122 |
Aerivio Spiromax |
Norway |
29.10.2019 |
EU/1/07/390 |
Altargo |
Iceland |
28.8.2019 |
EU/2/99/017 |
Bovalto Ibraxion |
Iceland |
16.7.2019 |
EU/1/14/939 |
Daklinza |
Iceland |
13.12.2019 |
EU/1/15/1077 |
Iblias |
Iceland |
10.9.2019 |
EU/1/15/1077 |
Iblias |
Liechtenstein |
31.10.2019 |
EU/1/15/1077 |
Iblias |
Norway |
3.9.2019 |
EU/2/17/208 |
Ingelvac PCV FLEX |
Norway |
23.08.2019 |
EU/1/19/1357 |
Kromeya |
Liechtenstein |
31.12.2019 |
EU/1/19/1357 |
Kromeya |
Norway |
17.12.2019 |
EU/1/16/1143 |
Lartruvo |
Iceland |
26.8.2019 |
EU/1/16/1143 |
Lartruvo |
Liechtenstein |
31.8.2019 |
EU/1/16/1143 |
Lartruvo |
Norway |
5.8.2019 |
EU/1/13/847 |
MACI |
Iceland |
6.11.2019 |
EU/1/16/1100 |
Palonosetron Hospira |
Iceland |
2.7.2019 |
EU/1/16/1100 |
Palonosetron Hospira |
Norway |
23.8.2019 |
EU/1/13/849 |
Somatropin Biopartners |
Norway |
26.8.2019 |
EU/1/16/1131 |
Thorinane |
Iceland |
6.11.2019 |
EU/1/09/552 |
Topotecan Teva |
Norway |
23.08.2019 |
EU/1/16/1121 |
Zalmoxis |
Iceland |
18.10.2019 |
EU/1/16/1121 |
Zalmoxis |
Norway |
30.10.2019 |
ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July–31 December 2019:
EU-Number |
Product |
Country |
Date of suspension |
|
|
|
|